Bellevue Life Sciences Acquisition Corp. (BLAC) Signs Letter of Intent with OSR Holdings
by Marlena Haddad on 2023-07-11 at 5:24pm

Bellevue Life Sciences Acquisition Corp. (Nasdaq: BLAC) has signed a non-binding letter of intent (LOI) to combine with global healthcare holding company OSR Holdings, Ltd.

Seoul, South Korea-based OSR leverages its international network of partners in the US, Europe, and South Korea to develop and license its pipeline of innovative biomedical therapies based on proprietary platform technologies, with the ultimate goal of addressing unmet medical needs.

Although Bellevue did not provide much information on the potential transaction, it expects to finalize the definitive agreement within the coming weeks and will announce additional details at that time. With a November 14 completion deadline, the parties intend to complete the business combination in the fourth quarter of 2023.

Upon completion of the business combination, the surviving company will be renamed OSR Biosciences, Inc.

OSR Holdings currently wholly owns three operating subsidiaries in Switzerland and South Korea, two of which are focused on developing therapeutic drugs in the areas of oncology and osteoarthritis, and the third is a distributor of medical devices for the treatment of neurovascular and other diseases.

Additionally, OSR Holdings signed a separate LOI on July 7 to acquire Landmark BioVentures AG, a Swiss company that operates through four different biotech ventures in France with therapeutic focuses on oncology and immunology.

Bellevue Life Sciences priced its $60 million IPO earlier this year in February and initially set out to acquire a target business in the healthcare industry, specifically in the biotechnology sector developing the next generation of biologics. The SPAC is led by CEO Kuk Hyuon Hwang, CFO David J. Yoo, and Nominee for Chairman of the Board Steven Reed.

 

Recent Posts
by Nicholas Alan Clayton on 2024-07-19 at 12:46pm

Vine Hill Capital Investment Corp. (NASDAQ:ESPAU) has filed for a $200 million IPO, which marks underwriter Stifel Nicolaus’ return to the SPAC market after a hiatus of over two years. Stifel last served as a book-runner for a SPAC when filing for Kensington Capital IV in January 2022 and hasn’t acted as left-lead since Spree...

by Nicholas Alan Clayton on 2024-07-19 at 8:13am

At the SPAC of Dawn SPACs may be back on the upswing, but it seems increasingly unlikely they will return to the same stomping grounds as in 2020-2022. Teams took 14 Fintech firms public during those years, 17 more in broader Financial Services and five more in Crypto. But, those sectors may no longer hold...

by Nicholas Alan Clayton on 2024-07-18 at 1:18pm

Expectation Acquisition Corporation (NASDAQ:ESPAU) has filed to bring another Oppenheimer alum back to the market with a $60 million SPAC IPO. That officer is Expectation CFO Chi Zhuang, who started out as an equity research associate at the firm’s New York office in 2014. This overlapped with a period when Lewis Silberman, co-CEO of yesterday’s...

by Kristi Marvin on 2024-07-18 at 10:19am

In the past few months we’ve seen a number of SPACs IPO using what we like to call “anchor investors”, a term we use as a bit of shorthand.  What that means is, the bankers round out the IPO with qualified institutional buyers, sometimes called “non-managing sponsor investors”, that indicate for up to 9.9% of...

by Nicholas Alan Clayton on 2024-07-18 at 8:20am

At the SPAC of Dawn Stardust Power (NASDAQ:SDST) is the latest de-SPAC to rocket up this week after closing its combination with Global Partner II, but there could be more to its spike than simply the low float it currently represents. The parties got through their July 8 closing with just 134,550 public shares remaining...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved